Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ares Capital Corporation (ARCC) vs BioNTech SE - ADR (BNTX) Price & Performance

Ares Capital CorporationTrade
BioNTech SE - ADRTrade

Price performance (Past 24H)

Key statistics

Ares Capital Corporation vs BioNTech SE - ADR — how do they compare? Ares Capital Corporation trades at $19.87 (market cap $14.34B), while BioNTech SE - ADR trades at $92.94 (market cap $23.31B). The key difference: BioNTech SE - ADR is the larger of the two by market cap, and Ares Capital Corporation pays a 9.61% dividend while BioNTech SE - ADR pays none. Which is the better fit depends on your goals.

ARCCBNTX
Market Cap
$14.34B$23.31B
Sector
FinancialsHealth
52-Week High
$22.68$119.34
52-Week Low
$17.45$83.89
Dividend Yield
9.61%
Enterprise Value
$6.60B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ares Capital Corporation

ARCC trades at $19.87, down 0.55% with a bullish technical outlook supported by moving averages. The company reported $1.51B revenue and $1.30B net income for 2025, maintaining an 86.25% profit margin. Recent earnings show slight misses against expectations, but dividend coverage remains stable at 104% with a 9.9% yield. Analyst consensus is strongly bullish with 24 buy ratings and a $19.63 price target.

The stock presents income appeal with its high dividend yield and stable payout history, though recent earnings compression and rising non-accruals to 2.4% signal credit quality concerns. Private credit sector strain and potential rate cuts pose medium-term risks to net investment income, which is 71% variable-rate exposed.

BioNTech SE - ADR

BioNTech (BNTX) trades at $92.72, down 0.09% on the day, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 revenue of €106 million, missing expectations due to weak COVID-19 vaccine demand, and lowered its 2026 sales outlook. Despite negative profitability metrics (net income margin -63.64%, ROE -9.3%), the balance sheet remains strong with $16.78 billion in cash. Analyst consensus is strongly bullish with 87.5% buy ratings and a $121 price target.

The outlook for BNTX hinges on its oncology pipeline development amid declining COVID revenue. Investment opportunity exists in the discounted valuation relative to cash reserves and potential pipeline catalysts. Key risks include execution on pipeline transitions, competitive pressure, and ongoing vaccine demand volatility. The stock trades near cash value, implying the market assigns minimal value to its advanced clinical programs.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Ares Capital Corporation

Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing primarily in U.S. middle-market companies with investment opportunities as well as in larger companies. Its portfolio comprises of first lien senior secured loans, second lien senior secured loans, and mezzanine debt (subordinated unsecured loan), which may include equity components that are diversified by industry and sector. The company may invest in preferred and common equity investments to a lesser proportion. Its revenue mainly consists of interest and dividend income received from the investment made.

Read more on ARCC

About BioNTech SE - ADR

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.

Read more on BNTX